Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Fortis considering...

    Fortis considering Vertical De-merger of SRL limited

    Written by Geeta Sharma Sharma Published On 2016-05-29T18:21:28+05:30  |  Updated On 13 Oct 2022 10:41 AM IST
    Fortis considering Vertical De-merger of SRL limited

    A de merger by revenues is an option being considered for SRL Ltd by its parent company Fortis Healthcare Ltd, before taking the subsidiary public, read an announcement made by the company on Thursday .The vertical de merger is being considered, in order to get Fortis listed on the Indian stock exchange and also help provide an exit passage to the private equity investors, who together with the parent group own 34 % of the stake. This de-merger would allow them to exit even if the proposed listings face delays in the future.The equity investors seeking exit are International Finance Corporation (IFC), NYLIM, Jacob Ballas and Avigo Capital Partners.


    Besides, Private Equity Asia, Bain Capital and Capital International, among others, were in talks to buy the stake from existing investors revealed reports in the Economic Times . "The deal could not materialize due the valuation difference," according to sources. SRL had taken on Moelis and Co, an investment bank, during this time last year to seek advice on the exit deal for present investors.The de merger move will also result in SRL ceasing to be a subsidiary of Fortis Healthcare.


    SRL's expectation to do well at the stock exchange received a new high, when the market rival Dr. Lal Path Labs did good with its stock market debut.



    "The successfully listing of Dr Lal Path labs Limited, in December 2015, has directly affected the promoters' expectation of SRL Diagnostics," said a source in the company. With Dr Lal Path labs having done its public issue at Rs. 550 per share in December 2015, leading to a valuation of Rs. 4,550 crore, it has been now observed that the company's share has almost doubled at Rs.977 in the last five months. Its market capitalization crossing from Rs. 8000 crores to Rs. 8091 crores.


    Fortis Healthcare on the other hand has a market capitalization of Rs. 7,830 crores and a current share price of Rs. 169.


    Owned by the Singh brothers Malwinder Mohan and Shivinder Mohan. Fortis Healthcare, were initially looking for a Rs. 6000 crore valuation, while the market was responding back at Rs. 4000 crore, according to market sources. The directive for sale was for a minority stake . Those close to the Fortis group, however, claim that options to the extent of an all out sale had also existed.


    Coming back to SRL, on March 31, 2016, SRL had a network of 314 labs and about 7200 collection centres. Performing over 14.5 million accessions during FY16, SRL witnessed a 6% growth over last year. With these accessions it undertook 32.7 million tests, up 8% compared with 30.4 million tests in FY15. Its revenues rose 6% to Rs. 764 crores last financial year; its pathology business contributing 88% to the revenue in the current year. Reflecting a 14% growth every year. The EBITA margin of SRL diagnostics is a few decimal points away from that of its closest competitor Dr. Lal Path labs according to VCC Circle


    Avigo Capital PartnersBain CapitalCapital InternationalDr Lal Path labsEBITAFortis Healthcare LtdIFCInternational Finance CorporationJacob BallasMoelis and CoNYLIMPrivate Equity AsiaSRL LtdVertical De merger
    Source : Inputs from the economic times

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Geeta Sharma Sharma
    Geeta Sharma Sharma
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok